3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Disease Exacerbation in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cebrián, C; Escartín, A; Esquivias, P; Esteva, F; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S | 1 |
Burnett, MS; Epstein, SE; Ogunmakinwa, J; Rott, D; Zalles-Ganley, A; Zhou, YF; Zhu, J | 1 |
Aleksic, N; Delgado, RM; Kar, B; Mann, DL; McKay, K; Nawar, MA; Sivasubramanian, N; Vaughn, WK; Willerson, JT; Wu, KK; Zewail, AM | 1 |
3 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Disease Exacerbation
Article | Year |
---|---|
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Barrett Esophagus; Cell Transformation, Neoplastic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Disease Progression; Esophageal Neoplasms; Esophagitis; Esophagus; Female; Furans; Gastroesophageal Reflux; Indomethacin; Membrane Proteins; Metaplasia; Mucous Membrane; Rats; Rats, Wistar; Time Factors | 2012 |
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
Topics: Animals; Antibodies, Viral; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; Disease Susceptibility; DNA, Viral; Dose-Response Relationship, Immunologic; Furans; Immunoglobulin G; Isoenzymes; Mice; Mice, Knockout; Prostaglandin-Endoperoxide Synthases; Viral Load; Virus Replication | 2003 |
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Doxorubicin; Drug Evaluation, Preclinical; Furans; Heart Failure; Inflammation Mediators; Isoenzymes; Mice; Prostaglandin-Endoperoxide Synthases; Reproducibility of Results; Single-Blind Method; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2004 |